American Journal of Kidney Diseases

Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies

Published:March 13, 2012DOI:


      Renal involvement is common in multiple myeloma. In this study, we examined kidney biopsy findings in patients with multiple myeloma and correlated them with their clinical renal and hematologic characteristics.

      Study Design

      Case series.

      Setting & Participants

      190 Mayo Clinic patients with multiple myeloma who underwent kidney biopsy between 1997-2011 were identified from our kidney biopsy database. Patients had an established diagnosis of multiple myeloma or multiple myeloma was diagnosed shortly after the results of kidney biopsy, which prompted bone marrow biopsy.


      Myeloma cast nephropathy (MCN), AL amyloidosis, and monoclonal immunoglobulin deposition disease (MIDD).

      Outcomes & Measurements

      Renal morphologic changes, clinical renal and hematologic characteristics at kidney biopsy, renal and patient outcomes.


      Paraprotein-associated lesions were seen in 73% of patients; non–paraprotein-associated lesions, in 25%; and no pathology, in 2%. The most common paraprotein-associated lesions were MCN (33%), MIDD (22%), and amyloidosis (21%). The most common non–paraprotein-associated lesions were acute tubular necrosis (9%), hypertensive arteriosclerosis (6%), and diabetic nephropathy (5%). Patients with MIDD were younger than those with MCN or amyloidosis. Urine paraprotein size and bone marrow plasma cell percentage were higher in MCN than amyloidosis or MIDD. Nephrotic syndrome was more common in amyloidosis than MIDD. Percentage of albuminuria was highest in amyloidosis and lowest in MCN. Median kidney survival from kidney biopsy was 20, 30, and 51 months for MCN, amyloidosis, and MIDD, respectively (P = 0.2). Median patient survival from multiple myeloma diagnosis was 44, 58, and 62 months for MCN, amyloidosis, and MIDD, respectively (P = 0.4).


      Retrospective nature.


      The spectrum of renal lesions in multiple myeloma is more heterogeneous than previously reported. Clinical features favoring amyloidosis over MIDD include older age, absence of kidney failure, presence of nephrotic syndrome, absence of hematuria, and >50% albuminuria.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brenner H.
        • Gondos A.
        • Pulte D.
        Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.
        Haematologica. 2009; 94: 270-275
        • Brenner H.
        • Gondos A.
        • Pulte D.
        Recent major improvement in long-term survival of younger patients with multiple myeloma.
        Blood. 2008; 111: 2521-2526
        • Knudsen L.M.
        • Hippe E.
        • Hjorth M.
        • Holmberg E.
        • Westin J.
        Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients.
        Eur J Haematol. 1994; 53: 207-212
        • Kyle R.A.
        • Gertz M.A.
        • Witzig T.E.
        • et al.
        Review of 1027 patients with newly diagnosed multiple myeloma.
        Mayo Clin Proc. 2003; 78: 21-33
        • Heher E.C.
        • Goes N.B.
        • Spitzer T.R.
        • et al.
        Kidney disease associated with plasma cell dyscrasias.
        Blood. 2010; 116: 1397-1404
        • Hill G.S.
        • Morel-Maroger L.
        • Méry J.P.
        • Brouet J.C.
        • Mignon F.
        Renal lesions in multiple myeloma: their relationship to associated protein abnormalities.
        Am J Kidney Dis. 1983; 2: 423-438
        • Pasquali S.
        • Zucchelli P.
        • Casanova S.
        • et al.
        Renal histological lesions and clinical syndromes in multiple myeloma.
        Clin Nephrol. 1987; 27: 222-228
        • Rota S.
        • Mougenot B.
        • Baudouin B.
        • et al.
        Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients.
        Medicine (Baltimore). 1987; 66: 126-137
        • Montseny J.J.
        • Kleinknecht D.
        • Meyrier A.
        • et al.
        Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies.
        Nephrol Dial Transplant. 1998; 13: 1438-1445
        • Durie B.G.
        • Kyle R.A.
        • Belch A.
        • et al.
        • Scientific Advisors of the International Myeloma Foundation
        Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
        Hematol J. 2003; 4: 379-398
        • Lin J.
        • Markowitz G.S.
        • Valeri A.M.
        • et al.
        Renal monoclonal immunoglobulin deposition disease: the disease spectrum.
        J Am Soc Nephrol. 2001; 12: 1482-1492
        • Soares S.M.
        • Fervenza F.C.
        • Lager D.J.
        • et al.
        Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients.
        Am J Kidney Dis. 2008; 52: 1079-1083
        • Herrera G.A.
        • Joseph L.
        • Gu X.
        • Hough A.
        • Barlogie B.
        Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia.
        Arch Pathol Lab Med. 2004; 128: 875-879
        • Oshima K.
        • Kanda Y.
        • Nannya Y.
        • et al.
        Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma.
        Am J Hematol. 2001; 67: 1-5
        • D'Agati V.D.
        • Jennette J.C.
        • Silva F.G.
        Atlas of Nontumor Pathology: Non-Neoplastic Kidney Diseases.
        in: American Registry of Pathology-Armed Forces Institute of Pathology, Washington, DC2005: 269-296
        • Nasr S.H.
        • Markowitz G.S.
        • Stokes M.B.
        • et al.
        Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis.
        Kidney Int. 2004; 65: 85-96
        • Messiaen T.
        • Deret S.
        • Mougenot B.
        • et al.
        Adult Fanconi syndrome secondary to light chain gammopathy.
        Medicine (Baltimore). 2000; 79: 135-154
        • Larsen C.P.
        • Bell J.M.
        • Harris A.A.
        • Messias N.C.
        • Wang Y.H.
        • Walker P.D.
        The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation.
        Mod Pathol. 2011; 24: 1462-1469
        • Markowitz G.S.
        • Appel G.B.
        • Fine P.L.
        • et al.
        Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
        J Am Soc Nephrol. 2001; 12: 1164-1172
        • Barri Y.M.
        • Munshi N.C.
        • Sukumalchantra S.
        • et al.
        Podocyte injury associated glomerulopathies induced by pamidronate.
        Kidney Int. 2004; 65: 634-641
        • Nasr S.H.
        • Fidler M.E.
        • Valeri A.M.
        • et al.
        Postinfectious glomerulonephritis in the elderly.
        J Am Soc Nephrol. 2011; 22: 187-195
        • Sanders P.W.
        • Herrera G.A.
        • Kirk K.A.
        • et al.
        Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition.
        Lab Invest. 1991; 64: 527-537
        • Child J.A.
        • Morgan G.J.
        • Davies F.E.
        • et al.
        • Medical Research Council Adult Leukaemia Working Party
        High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
        N Engl J Med. 2003; 348: 1875-1883
        • Attal M.
        • Harousseau J.L.
        • Stoppa A.M.
        • et al.
        A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.
        N Engl J Med. 1996; 335: 91-97
        • Chang A.
        • Hingorani S.
        • Kowalewska J.
        • et al.
        Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature.
        Clin J Am Soc Nephrol. 2007; 2: 1014-1023
        • Troxell M.L.
        • Pilapil M.
        • Miklos D.B.
        • Higgins J.P.
        • Kambham N.
        Renal pathology in hematopoietic cell transplantation recipients.
        Mod Pathol. 2008; 21: 396-406
        • Chan G.S.
        • Lam M.F.
        • Au W.Y.
        • et al.
        Clinicopathologic analysis of renal biopsies after haematopoietic stem cell transplantation.
        Nephrology (Carlton). 2008; 13: 322-330